Marco Meglio

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

During Cerebral Palsy Awareness Month, leaders in the field expressed their love for the CP community, the progress made in managing the disorders, and the steps needed to advance care into a realm never before seen.

The overall attributable fraction of multiple sclerosis due was 13.1%, in comparison with just 0.6% of ex-smokers, indicating the beneficial effects of smoking cessation.

Perceived negative effects on health care included disruption of interventional treatments that required in-person contact, concerns about losing healthcare providers, reluctance to use urgent care, and difficulty in obtaining certain medications due to shortages.

The risk of autism after perinatal ischemic stroke and childhood stroke was 2.7-fold and 3.30-fold, respectively, compared with matched controls in the study.

The founding chair of the department of brain health at UNLV discussed a recently awarded NIH grant dedicated to advancing neuroscience research for the long-term future.

In addition to the moderating role of age and sex, investigators found that high-sensitivity C-reactive protein moderated some associations between OSA risk and attention and episodic memory.

Eleven of the 12 individuals demonstrated at least a 50% reduction in creatine kinase, with 75% of participants reaching twice the normal range, suggesting a reduction in muscle breakdown.

More than 90% of the 65-patient cohort had evidence of normal swallowing and had no aspiration or pneumonia aspiration events reported in the phase 1 START and phase 3 STRIVE-EU and STRIVE-US trials.

In terms of cardiomyopathy, disease-modifying bioactivity of cardiosphere-derived cells was shown by improvements in left ventricular ejection fraction, a commonly used measure of global heart function.

Kaplan-Meier estimates showed a 61% decreased risk of death on CNM-Au8 compared with predicted median survival from a published European Network to Cure ALS model.

The American Academy of Sleep Medicine has previously pointed to evidence showing that the sudden change from standard time to daylight saving time is associated with significant public health, safety risks, and circadian rhythm.

The newly awarded grant will build upon the efforts of phase 1, the foundation of a research infrastructure, which consisted of several different innovative projects aimed at understanding commonalities of neurodegenerative disorders.

After a mean follow-up of 64 days, the most common adverse events were infections and vomiting, with no deaths or reports of post-lumbar puncture syndrome.

Using qualitative exploratory and quantitative validated questionnaires, investigators saw preparation and assessment time reduced by one-third, with a 60% increase in patient encounters to subspecialty services, compared with the period prior to the COVID-19 pandemic.

Amyloid-related imaging abnormalities, a concern for patients receiving aducanumab, were nearly all resolved during the 132-week period.

Vamorolone, an investigational agent for Duchenne muscular dystrophy, showed an initial disease-modifying effect that was maintained over a follow-up period of 48 weeks.

The neurologist and assistant professor at the University of Toronto discussed advantages hyperspectral retinal imaging tools like RetiSpec offer and when clinicians can expect to see them in clinical settings.

Part B of the 2-part study will have patients previously on placebo receive SRP-9001 for an additional 52 weeks.

After being originally approved as a generic medication in 1996, a new transdermal formulation of donepezil is expected to be available for patients with Alzheimer disease in the fall of 2022.

Individuals on ravulizumab demonstrated statistically significant changes in the primary end point of MG-ADL and in secondary end points such as Quantitative Myasthenia Gravis total score.

At 97 weeks, avalglucosidase alfa showed continued benefit on measures such as forced vital capacity and 6-minute walk test distance and was successful for patients who switched off algucosidase alfa.

At months 6, 9, and 12 of treatment with daridorexant—which was recently FDA-approved for insomnia—patients improved on several sleep measures, including subjective total sleep time and daytime functioning.

Most of the 52 cognitive resilience proteins were found to be specific for cognitive decline and about 30% may provide resilience for both cognitive and noncognitive AD phenotypes.

Patients with chronic migraine on 60-mg once-daily and 30-mg twice-daily atogepant demonstrated reductions of 6.88 and 7.46 monthly migraine days, respectively, over a 12-week period.

In the EVOKE study (NCT02924129), the spinal cord stimulation system demonstrated superior pain relief compared to open-loop SCS at 12 months with no increase in pain medication.

Infection-related epilepsy etiology, experiencing multiple types of seizures, and cognitive impairment were independent influencing factors on perampanel use retention.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

More than half of the patients with episodic migraine considered the likelihood of migraine on day 1 postdosing to be as important as the reduction in migraines in the days to follow.